Gestiva in a Catch-22
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA says it will not approve KV Pharmaceuticals' pregnancy drug Gestiva until the firm makes revisions to a post-approval trial protocol and meets an enrollment goal for that trial. The agency and KV had agreed to FDA-suggested revisions to the protocol, but added other conditions for approval, including that the trial must have a specified portion of study subjects enrolled prior to final approval. The firm announced receipt of FDA's "complete response" letter Jan. 26. But KV is running out of money and isn't due to get funds from Hologic, its marketing partner for Gestiva, until the drug is approved. On Feb. 9 KV said it would reduce its workforce by 700. Gestiva (alpha hydroxyprogesterone caproate) is intended to prevent preterm birth in at-risk women
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.